Skip Nav Destination
Issues
Inhibiting ERK5 Overcomes Breast Cancer Resistance to Anti-HER2 Therapy By Targeting the G1–S Cell-Cycle Transition
Jingwei Zhang; Adam J. Pearson; Nitin Sabherwal; Brian A. Telfer; Nisha Ali; Karmern Kan; Qiuping Xu; Wei Zhang; Fuhui Chen; Shiyang Li; Jinhua Wang; Nathanael S. Gray; Blanca Risa-Ebrí; Katherine G. Finegan; Michael J. Cross; Emanuele Giurisato; Alan J. Whitmarsh; Cathy Tournier
Conduit CAR: Redirecting CAR T-Cell Specificity with A Universal and Adaptable Bispecific Antibody Platform
M. Jack Borrok; Yonghai Li; Paul B. Harvilla; Bharathikumar Vellalore Maruthachalam; Ninkka Tamot; Christine Prokopowitz; Jun Chen; Sathya Venkataramani; Iqbal S. Grewal; Rajkumar Ganesan; Sanjaya Singh
Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors
Ana M. Metelo; Agnieszka Jozwik; Le Anh Luong; Delaney Dominey-Foy; Charlotte Graham; Charlotte Attwood; Shafqat Inam; Alan Dunlop; Katy Sanchez; Kirsty Cuthill; Carmel Rice; Matthew Streetly; Trevor Bentley; Bijan Boldajipour; Cesar Sommer; Barbra Sasu; Reuben Benjamin
MYCMI-7: A Small MYC-Binding Compound that Inhibits MYC: MAX Interaction and Tumor Growth in a MYC-Dependent Manner
Alina Castell; Qinzi Yan; Karin Fawkner; Wesam Bazzar; Fan Zhang; Malin Wickström; Mohammad Alzrigat; Marcela Franco; Cecilia Krona; Donald P. Cameron; Cecilia Dyberg; Thale Kristin Olsen; Vasiliki Verschut; Linnéa Schmidt; Sheryl Y. Lim; Loay Mahmoud; Per Hydbring; Sören Lehmann; Laura Baranello; Sven Nelander; John Inge Johnsen; Lars-Gunnar Larsson
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds